SI2776032T1 - Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom - Google Patents
Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesomInfo
- Publication number
- SI2776032T1 SI2776032T1 SI201231459T SI201231459T SI2776032T1 SI 2776032 T1 SI2776032 T1 SI 2776032T1 SI 201231459 T SI201231459 T SI 201231459T SI 201231459 T SI201231459 T SI 201231459T SI 2776032 T1 SI2776032 T1 SI 2776032T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- hematologic malignancies
- cxcr4 antibody
- cxcr4
- antibody
- Prior art date
Links
- 208000002250 Hematologic Neoplasms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| EP12787343.8A EP2776032B1 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2776032T1 true SI2776032T1 (sl) | 2018-12-31 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231459T SI2776032T1 (sl) | 2011-11-09 | 2012-11-09 | Zdravljenje hematoloških malignih obolenj z anti-CXCR4 protitelesom |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (enExample) |
| EP (1) | EP2776032B1 (enExample) |
| JP (1) | JP6541350B2 (enExample) |
| KR (1) | KR102024957B1 (enExample) |
| CN (1) | CN104039320B (enExample) |
| AU (1) | AU2012335553B2 (enExample) |
| BR (1) | BR112014011144A2 (enExample) |
| CA (1) | CA2855155A1 (enExample) |
| CY (1) | CY1121331T1 (enExample) |
| DK (1) | DK2776032T3 (enExample) |
| EA (1) | EA026153B1 (enExample) |
| ES (1) | ES2705001T3 (enExample) |
| HR (1) | HRP20182183T1 (enExample) |
| HU (1) | HUE043001T2 (enExample) |
| IL (1) | IL232517B (enExample) |
| LT (1) | LT2776032T (enExample) |
| MX (1) | MX357100B (enExample) |
| PL (1) | PL2776032T3 (enExample) |
| PT (1) | PT2776032T (enExample) |
| RS (1) | RS58102B1 (enExample) |
| SG (1) | SG11201401386XA (enExample) |
| SI (1) | SI2776032T1 (enExample) |
| SM (1) | SMT201900026T1 (enExample) |
| WO (1) | WO2013071068A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54424B1 (sr) * | 2006-10-02 | 2016-04-28 | E. R. Squibb & Sons, L.L.C. | Humana antitela koja se vezuju za cxcr4 i njihove upotrebe |
| WO2013006443A2 (en) | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| AU2014318614B2 (en) * | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
| EP3599248A1 (en) * | 2013-11-06 | 2020-01-29 | Bristol-Myers Squibb Company | Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody |
| US10612095B2 (en) | 2013-12-06 | 2020-04-07 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
| EP3079683A4 (en) | 2013-12-13 | 2017-12-20 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| KR102775902B1 (ko) * | 2013-12-17 | 2025-03-06 | 크링 바이오테라퓨틱스 비.브이. | 골수 증식성 또는 림프 증식성 질환에 대응하는 수단 및 방법 |
| WO2015118538A1 (en) * | 2014-02-06 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
| AU2014383868A1 (en) * | 2014-02-19 | 2016-09-08 | MicroConstants China Inc, Disabled Disabled Disabled | Chemokine receptor antagonist and its combinational therapy |
| DK3242685T3 (da) * | 2015-01-09 | 2022-07-25 | Adalta Ltd | Cxcr4-bindende molekyler |
| RS60753B1 (sr) | 2015-04-17 | 2020-10-30 | Bristol Myers Squibb Co | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| JP2018516969A (ja) | 2015-06-12 | 2018-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| US11219694B2 (en) | 2015-09-24 | 2022-01-11 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| CA3004772A1 (en) * | 2015-11-09 | 2017-05-18 | The General Hospital Corporation D.B.A Massachusetts General Hospital | Unit dose formulations for use as an anti-fugetactic agent |
| WO2017145161A1 (en) * | 2016-02-23 | 2017-08-31 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| JP2019518006A (ja) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｙｄ８８変異型疾患における治療標的としてのｈｃｋ |
| KR102369735B1 (ko) | 2016-05-20 | 2022-03-02 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | 암을 치료하기 위한 면역요법과의 글루타메이트 조정제의 용도 |
| US20190175557A1 (en) * | 2016-06-16 | 2019-06-13 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
| US20190389958A1 (en) * | 2017-01-31 | 2019-12-26 | Msm Protein Technologies, Inc. | Anti-cxcr4 antibodies |
| TWI693074B (zh) * | 2017-02-21 | 2020-05-11 | 美商庫拉腫瘤技術股份有限公司 | 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症之方法 |
| SG11201908396PA (en) | 2017-03-31 | 2019-10-30 | Bristol Myers Squibb Co | Methods of treating tumor |
| US20200239577A1 (en) | 2017-10-15 | 2020-07-30 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2019113456A1 (en) * | 2017-12-08 | 2019-06-13 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| WO2019175802A1 (en) | 2018-03-13 | 2019-09-19 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| KR102761890B1 (ko) | 2018-03-23 | 2025-02-06 | 브리스톨-마이어스 스큅 컴퍼니 | Mica 및/또는 micb에 대한 항체 및 그의 용도 |
| CN111918873B (zh) | 2018-03-27 | 2025-06-24 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| CN111971306A (zh) | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| CN114245869A (zh) | 2019-05-23 | 2022-03-25 | 百时美施贵宝公司 | 监测细胞培养基的方法 |
| EP4225770A1 (en) | 2020-10-05 | 2023-08-16 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| JP2025509274A (ja) | 2022-03-09 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | 治療用タンパク質の一過性発現 |
| AR131718A1 (es) * | 2023-01-30 | 2025-04-23 | Kymab Ltd | Anticuerpos |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119119196B (zh) * | 2024-08-01 | 2025-09-09 | 青岛大学 | 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| ATE378403T1 (de) | 2000-11-30 | 2007-11-15 | Medarex Inc | Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern |
| WO2005024015A1 (en) | 2003-09-04 | 2005-03-17 | Medarex, Inc. | Expression vector |
| US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| EP2029155B1 (en) * | 2006-02-28 | 2016-04-13 | Pharma Mar S.A. | Improved treatment of multiple myeloma |
| RS54424B1 (sr) * | 2006-10-02 | 2016-04-28 | E. R. Squibb & Sons, L.L.C. | Humana antitela koja se vezuju za cxcr4 i njihove upotrebe |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| CN102027015A (zh) * | 2008-05-14 | 2011-04-20 | 伊莱利利公司 | 抗cxcr4抗体 |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| AU2010224125B2 (en) | 2009-03-12 | 2015-05-14 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| CN102460165B (zh) | 2009-05-19 | 2016-08-17 | 维维雅生物技术公司 | 用于为血液肿瘤提供离体个体化药物测试的方法 |
| MX2013002051A (es) | 2010-08-20 | 2013-06-28 | Cerulean Pharma Inc | Particulas, composiciones y conjugados de peptido terapeutico-polimero y metodos relacionados. |
-
2012
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/zh not_active Expired - Fee Related
- 2012-11-09 EA EA201490957A patent/EA026153B1/ru not_active IP Right Cessation
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/lt unknown
- 2012-11-09 ES ES12787343T patent/ES2705001T3/es active Active
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 MX MX2014005267A patent/MX357100B/es active IP Right Grant
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en not_active Ceased
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/ko not_active Expired - Fee Related
- 2012-11-09 SM SM20190026T patent/SMT201900026T1/it unknown
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/hu unknown
- 2012-11-09 RS RS20181552A patent/RS58102B1/sr unknown
- 2012-11-09 PL PL12787343T patent/PL2776032T3/pl unknown
- 2012-11-09 HR HRP20182183TT patent/HRP20182183T1/hr unknown
- 2012-11-09 SI SI201231459T patent/SI2776032T1/sl unknown
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 PT PT12787343T patent/PT2776032T/pt unknown
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/ja not_active Expired - Fee Related
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/pt not_active Application Discontinuation
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/el unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201401386XA (en) | Treatment of hematologic malignancies with an anti-cxcr4 antibody | |
| IL228738A0 (en) | Antibodies for cancer treatment | |
| EP2760452A4 (en) | METHODS OF TREATING CANCER | |
| IL232055B (en) | Anti-1htra antibodies and methods of use | |
| ZA201403760B (en) | Anti-cd98 antibodies and methods of use thereof | |
| PT2768857T (pt) | Métodos para purificar anticorpos | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| EP2717855A4 (en) | PROCESSING METHODS | |
| IL232510A0 (en) | Treatment methods using an antibody against gamma interferon | |
| EP2736330A4 (en) | COMPOUNDS AND METHODS | |
| HUE048876T2 (hu) | Rákos megbetegedések kezelése | |
| EP2734234A4 (en) | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF | |
| PL2739153T3 (pl) | Leczenie raka sutka | |
| EP2736332A4 (en) | CONNECTIONS AND METHODS | |
| EP2736329A4 (en) | COMPOUNDS AND METHODS | |
| EP2798087A4 (en) | CELL ANALYSIS OF ORGANIC LIQUIDS | |
| IL228430A0 (en) | Cancer treatment | |
| EP2731429A4 (en) | COMPOUNDS, METHODS OF PREPARATION AND METHODS OF USE | |
| EP2709999A4 (en) | QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE | |
| ZA201403739B (en) | Methods of treatment with deferiprone | |
| EP2785742A4 (en) | ANTI-KDR ANTIBODIES AND METHOD OF USE THEREOF | |
| IL228706A0 (en) | Divided conduit and process for forming | |
| GB201121564D0 (en) | Use of antibody | |
| IL232266A0 (en) | Cancer treatment methods | |
| IL229109A0 (en) | Cancer diagnosis |